Sionna Therapeutics Q4 2025 net loss $20.4M; cash $310.3M funds into 2028

Sionna Therapeutics, Inc.

Net loss $20.4M (Q4) and $75.3M (FY 2025) vs $15.8M and $61.7M in 2024.
Cash and equivalents $310.3M as of Dec 31, 2025; expected to fund operations into 2028.
Phase 2a PreciSION CF trial of SION-719 on track; topline data expected mid-2026.
Phase 1 dual combo trial of SION-451 with SION-2222/SION-109 on track; data mid-2026.
R&D expenses $15.2M (Q4) and $60.3M (FY); G&A expenses $8.4M (Q4) and $28.7M (FY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.